LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aktien・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

98.06 2.7

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

95.48

Max

100.3

Schlüsselkennzahlen
By Trading Economics
Einkommen	-6.3M -53M
Verkäufe	2.8M 51M
EPS	-0.82
Gewinnspanne	-103.131
Angestellte	283
EBITDA	-7.6M -48M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+36.94% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	25. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-616M 6.9B
Vorheriger Eröffnungskurs	95.36
Vorheriger Schlusskurs	98.06

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

60 / 65.58 Unterstützung & Widerstand

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Feb. 2026, 16:32 UTC

Ergebnisse

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13. Feb. 2026, 21:57 UTC

Ergebnisse

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Feb. 2026, 21:20 UTC

Ergebnisse

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13. Feb. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13. Feb. 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Feb. 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13. Feb. 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13. Feb. 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13. Feb. 2026, 19:51 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:29 UTC

Ergebnisse

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13. Feb. 2026, 18:18 UTC

Akquisitionen, Fusionen, Übernahmen

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13. Feb. 2026, 17:52 UTC

Ergebnisse

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13. Feb. 2026, 17:16 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 17:10 UTC

Akquisitionen, Fusionen, Übernahmen

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13. Feb. 2026, 16:59 UTC

Ergebnisse

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13. Feb. 2026, 16:39 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13. Feb. 2026, 16:11 UTC

Ergebnisse

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13. Feb. 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13. Feb. 2026, 15:54 UTC

Ergebnisse

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13. Feb. 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13. Feb. 2026, 15:01 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13. Feb. 2026, 15:00 UTC

Ergebnisse

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13. Feb. 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13. Feb. 2026, 14:44 UTC

Ergebnisse

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13. Feb. 2026, 14:22 UTC

Market Talk

Ergebnisse

Global Energy Roundup: Market Talk

13. Feb. 2026, 14:21 UTC

Market Talk

Ergebnisse

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13. Feb. 2026, 14:13 UTC

Market Talk

U.S. Natural Gas Futures Move Lower -- Market Talk

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

36.94% Vorteil

12-Monats-Prognose

Durchschnitt 142.38 USD 36.94%

Hoch 167 USD

Tief 125 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.